From production to patient: challenges and approaches for delivering cell therapies

The cell therapy industry is rapidly growing with several new products approved for clinical use over the past few years and many more currently in clinical trials. Nonetheless, a number of challenges remain in getting cell therapies to the market and into routine use. For instance, cell therapy bioprocesses still need to be optimised, but if these therapies are to be widely adopted there must also be clear routes for their delivery from the site of manufacture to the clinic and the patients. This review explores the currently available routes, the factors that need to be taken into consideration when choosing a route and the challenges that remain with respect to cell therapy logistics.

• Publication year

  2014

• Venue

  Stembook

• Publication date

  2014-03-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.3824/STEMBOOK.1.97.1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Institutional Repository Application of response surface methodology to maximize the productivity of scalable automated human embryonic stem cell manufacture

  2017cited by this paper
• Mesenchymal Stem Cells for Regenerative Therapy: Optimization of Cell Preparation Protocols

  2014cited by this paper
• Measures of stored red blood cell quality

  2014cited by this paper
• MSC-based product characterization for clinical trials: an FDA perspective.

  2014cited by this paper
• iPS cells: a game changer for future medicine

  2014cited by this paper
• Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion

  2014influential reference
• Experience of ReCell in Skin Cancer Reconstruction

  2013cited by this paper
• Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry.

  2013cited by this paper
• To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors

  2013cited by this paper
• Manufacturing and banking of mesenchymal stem cells

  2013cited by this paper
• Low temperature cell pausing: an alternative short-term preservation method for use in cell therapies including stem cell applications

  2013cited by this paper
• Cell adhesion and mechanical stimulation in the regulation of mesenchymal stem cell differentiation

  2013cited by this paper
• Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications.

  2013cited by this paper
• The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?

  2013cited by this paper
• Automation of cell therapy biomanufacturing

  2013cited by this paper
• Allogeneic Cell Therapy Bioprocess Economics and Optimization: Single-Use Cell Expansion Technologies

  2013cited by this paper
• Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: case studies.

  2013cited by this paper
• Large-scale expansion and exploitation of pluripotent stem cells for regenerative medicine purposes: beyond the T flask.

  2012cited by this paper
• An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion

  2012cited by this paper
• Scientific problems in the regulation of red blood cell products

  2012cited by this paper
• Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide

  2012cited by this paper
• The sensitivity of human mesenchymal stem cells to vibration and cold storage conditions representative of cold transportation

  2012cited by this paper
• Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing

  2011influential reference
• Cryopreservation of Human Stem Cells for Clinical Application: A Review

  2011cited by this paper
• Large‐scale compatible methods for the preservation of human embryonic stem cells: Current perspectives

  2011cited by this paper
• Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine.

  2011cited by this paper
• Cell therapy industry: billion dollar global business with unlimited potential.

  2011influential reference
• Use of Reduced Temperature Cell Pausing to Enhance Flexibility of Cell-Based Assays

  2009cited by this paper
• Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.

  2009cited by this paper
• Biochemical insights into the mechanisms central to the response of mammalian cells to cold stress and subsequent rewarming

  2009cited by this paper
• Principles and overview of allogeneic hematopoietic stem cell transplantation.

  2009cited by this paper
• Hypothermic storage of isolated human hepatocytes: a comparison between University of Wisconsin solution and a hypothermosol platform

  2009cited by this paper
• Hematopoietic engraftment of dimethyl sulfoxide–depleted autologous peripheral blood progenitor cells

  2009cited by this paper
• Clinical Grade Treg: GMP Isolation, Improvement of Purity by CD127pos Depletion, Treg Expansion, and Treg Cryopreservation

  2008cited by this paper
• Characterization of adipose tissue-derived cells isolated with the Celution system.

  2008cited by this paper
• Collection, Processing and Infusion of Adult Hematopoietic Stem Cells (Bone Marrow and Peripheral Blood Stem Cells)

  2007cited by this paper
• Has allogeneic stem cell cryopreservation been given the ‘cold shoulder’? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation

  2006cited by this paper
• Cryopreservation of hematopoietic and non-hematopoietic stem cells.

  2006cited by this paper
• Cryopreservation of isolated human hepatocytes for transplantation: State of the art.

  2006cited by this paper
• Cryopreservation: It's Not Just About Cell Yield

  2005cited by this paper
• Evaluation of an automated cell processing device to reduce the dimethyl sulfoxide from hematopoietic grafts after thawing

  2005cited by this paper
• Cell Preservation in Reparative and Regenerative Medicine: Evolution of Individualized Solution Composition

  2004cited by this paper
• Preclinical evaluation of an automated closed fluid management device: CytomateTM, for washing out DMSO from hematopoietic stem cell grafts after thawing

  2003influential reference
• Cryopreserved Dermal Implants

  2002cited by this paper
• HPC viability measurement: trypan blue versus acridine orange and propidium iodide

  2000cited by this paper
• Comparison of Trypan Blue Dye Exclusion and Fluorometric Assays for Mammalian Cell Viability Determinations

  1993cited by this paper

• One-day rapid sterility test for human-derived biopharmaceuticals.

  2025cites this paper
• Report from the 2023 NIST-Hosted Workshop on Collaborative Efforts to Enable Adoption of Rapid Microbial Testing Methods for Advanced Therapy Products

  2025cites this paper
• Clinical Benefit of Autologous Platelet-Rich Plasma Infusion in Ovarian Function Rejuvenation: Evidence from a Before-After Prospective Pilot Study

  2023cites this paper
• A comprehensive review of quantum bioreactor cell manufacture: Research and clinical applications.

  2023cites this paper
• Hypothermic Storage of 3D Cultured Multipotent Mesenchymal Stromal Cells for Regenerative Medicine Applications

  2022cites this paper
• State-of-the-art knowledge on the regulation of advanced therapy medicinal products.

  2022cites this paper
• The Promise and the Hope of Gene Therapy

  2021cites this paper
• Identification of hurdles in the development of cell-based therapies.

  2020cites this paper
• Formulation of cell-based medicinal products: a question of life or death?

  2020cites this paper
• Current Applications of Pharmaceutical Biotechnology

  2020cites this paper
• Cell Therapy for Liver Disease: From Promise to Reality

  2020cites this paper
• Evaluation of Surface Modified Live Biotherapeutic Products for Oral Delivery.

  2020cites this paper
• Células estromales mesenquimales representan una opción terapéutica en pacientes con esclerosis sistémica

  2020cites this paper
• Cryopreservation as a Key Element in the Successful Delivery of Cell-Based Therapies—A Review

  2020cites this paper
• Mesenchymal stromal cells represent a therapeutic option for systemic sclerosis patients

  2020cites this paper
• Osteochondral Repair and Electromechanical Evaluation of Custom 3D Scaffold Microstructured by Direct Laser Writing Lithography

  2019cites this paper
• Clinically Relevant Solution for the Hypothermic Storage and Transportation of Human Multipotent Mesenchymal Stromal Cells

  2019cites this paper
• Addressing the Manufacturing Challenges of Cell-Based Therapies.

  2019cites this paper
• Intra-articular Injection of Culture-Expanded Mesenchymal Stem Cells Without Adjuvant Surgery in Knee Osteoarthritis: A Systematic Review and Meta-analysis

  2019cites this paper
• The Role of Dissolved Oxygen Levels on Human Mesenchymal Stem Cell Culture Success, Regulatory Compliance, and Therapeutic Potential

  2018cites this paper
• Impact of allogeneic stem cell manufacturing decisions on cost of goods, process robustness and reimbursement

  2018cites this paper
• 19F-MRI to Monitor Therapeutic Cell Migration and Distribution

  2018cites this paper
• Cryopreservation of Human Adipose-Derived Stem Cells for Use in Ex Vivo Regional Gene Therapy for Bone Repair

  2018cites this paper
• Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges

  2018cites this paper
• Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.

  2018cites this paper
• Bioengineering Solutions for Manufacturing Challenges in CAR T Cells

  2018cites this paper
• Manufacturing of human mesenchymal stem cells : the analytical challenges

  2018cites this paper
• mpact of allogeneic stem cell manufacturing decisions on cost of oods , process robustness and reimbursement ania

  2018cites this paper
• The role of biopreservation in cell and gene therapy bioprocessing

  2017cites this paper
• 
Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan


  2017cites this paper
• Multifactorial analysis of mesenchymal stem cell properties for storage and transportation

  2017influential citation
• An ultra scale‐down methodology to characterize aspects of the response of human cells to processing by membrane separation operations

  2017cites this paper
• Storage and Delivery of Stem Cells for Cellular Therapies

  2016cites this paper
• Gene-modified, cell-based therapies-an overview.

  2016cites this paper
• Value creation in the cell therapy industry The role of regulation

  2016cites this paper
• Low-temperature pausing : an alternative short-term preservation method for use in cell therapies

  2016influential citation
• Automation of CAR-T cell adoptive immunotherapy bioprocessing: Technology opportunities to debottleneck manufacturing

  2016cites this paper
• Scalable Manufacture for Cell Therapy Needs

  2016cites this paper
• The translation of cell-based therapies: clinical landscape and manufacturing challenges.

  2015cites this paper
• Rapid phenotypic fingerprinting of cell products by robust measurement of ubiquitous surface markers

  2015cites this paper